Finanzen von Assembly Biosciences Inc (ASMB)ASMBAssembly Biosciences Inc

Evaluating the bottom line, Assembly Biosciences Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -47.44%, while the net margin is -28.84%. These profitability ratios, combined with a Return on Equity (ROE) of -0.03%, provide a clear picture of how effectively ASMB converts its operational activities into shareholder value.

In the context of the broader market, ASMB competes directly with industry leaders such as INDP and EIKN. With a market capitalization of $409.04M, it holds a significant position in the sector. When comparing efficiency, ASMB's gross margin of 100.00% stands against INDP's N/A and EIKN's N/A. Such benchmarking helps identify whether Assembly Biosciences Inc is trading at a premium or discount relative to its financial performance.

The company has shown fluctuating revenue growth, with Q2 2026 revenue at $13.37 million, up from $8.21 million in Q1 2026. However, it has reported net income losses in recent quarters, with a notable loss of $3.86 million in Q2 2026.